Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by ANALIAS00on Feb 11, 2019 6:54pm

166 Views

Post# 29349956

RE:RE:Gilead NASH Phase 3 fail....wonder if they go for Egrifta?

They will also be challenging their staff, they are probably already working on plan B and C. Not to sure buying TH or any other is part of their paln at ths point. But I hope I can be surprise... by the result first and by Gilead's intention :o)

palinc2000 wrote: More Gilead Phase 3 and Phase 2 trial results later this year
but they will surely take a close look at the results coming from the Egrifta trial

Gilead's selonsertib flunks late-stage NASH study
https://seekingalpha.com/news/3431904